Product Development Advisory Committee
The Product Development Advisory Committee (PDAC) provides expertise to the Oversight Committee on the growing gap between translational discovery and later stage clinical development of new oncology drugs in Texas. Primarily, it is making recommendations on the breadth of life science expertise needed in Texas to advance the state’s ability to improve cancer patient outcomes from promising scientific discoveries.
Related Documents:
Product Development Advisory Committee Annual Report 2024Product Development Advisory Committee Annual Report 2023
Members:
|
Andrew Strong, JD, Chair
|
|
Michele Park, Ph.D., Vice-Chair
|
|
Claire Aldridge, Ph.D.
|
|
David Arthur
|
|
Bruce Butler, Ph.D.
|
|
Gabby Everett, Ph.D.
|
|
Victoria Ford
|
|
Julie Goonewardene
|
|
Heather Hanson
|
|
Dan Hargrove, JD, LLM
|
|
Paul Lammers, M.D.
|
|
David Lowe, Ph.D.
|
|
Tom Luby, Ph.D.
|
|
Jonathan MacQuitty, Ph.D.
|
|
Dennis McWilliams
|
|
Jon Mogford, Ph.D.
|
|
Emily Reiser, Ph.D.
|
|
Emma Schwartz
|
|
Greg Stein, M.D.
|
|
Ann Tanabe
|